A logo design on the Sanofi exhibit area at the Viva Technology conference devoted to development and start-ups at Porte de Versailles exhibit center in Paris, France June 15, 2022.
Benoit Tessier|Reuters
French district attorneys have actually opened an initial examination into international pharmaceutical business Sanofi over possible market control.
A judicial source validated to CNBC on Tuesday that the Parquet National Financier, the French monetary district attorney, opened an initial probe in March 2023 into counts of “dissemination of false or misleading information and price manipulation,” associating with the business’s previous monetary interactions.
“Sanofi is not aware of any preliminary investigation on its 2017 accounts or other matter by the Parquet National Financier. We stand by the accuracy of our accounts,” Sanofi stated in an emailed declaration.
“As a listed company, the financial information published by Sanofi is accurate, precise and sincere, and is duly audited by two auditing firms. Sanofi reserves the right to take legal action against any false or defamatory allegations.”
The pharmaceutical giant late last month lowered its projections for 2024/ 5 and saw its share rate fall dramatically, now down 6.8% on the year.
— CNBC’s Charlotte Reed added to this report.
